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Angiogenesis occurs during development and repre-
sents a physiological response to environmental cues
(1). Neovessel formation also occurs in response to
stress (wound repair) (2) and in pathological situa-
tions later in life, such as tumor formation (3, 4) and
recanalization of thrombi after ischemic events (5).
Among the factors that mediate angiogenesis, VEGF
has been the subject of extensive research because of
its selective effect on endothelial cells (6). As a part of
the adaptive responses that achieve angiogenesis,
hypoxia-mediated induction of VEGF has been
demonstrated in a wide variety of cells, including
tumor cells (7), astrocytes (8), and cardiomyocytes (9).
Furthermore, expression of receptors for angiogenic
factors is also enhanced under hypoxia (10).
Exposure of cells to hypoxia triggers another series of
responses, including induction of a set of polypeptides
termed oxygen-regulated proteins (ORPs) (11). In this
context, astrocytes provide a particularly relevant cell
type for analysis of the response to hypoxia, because
they demonstrate robust viability and even produce
neurotrophic cytokines under hypoxia (12). We have
purified and cloned an ORP with a molecular mass of
150 kDa (termed ORP150) from primary cultures of
astrocytes (13, 14). ORP150 is an inducible endoplas-
mic reticulum (ER) chaperone and is expressed in a
range of pathologic situations, such as ischemic brain
(15), atherosclerotic plaques (16), and malignant
tumors (17). These data suggest that ORP150 may con-
tribute in a fundamental way to the cellular response
to environmental stress.
The current study demonstrates expression of
ORP150 in healing of human wounds. In vivo gene-
transfer studies showed that infection of wounds with
an adenovirus causing overexpression of ORP150 accel-
erated wound closure (and expression of VEGF anti-
gen), whereas suppression of ORP150 delayed the repar-
ative processes (and suppressed VEGF antigen
expression). These findings suggest an as yet unexplored
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Expression of angiogenic factors such as VEGF under conditions of hypoxia or other kinds of cell
stress contributes to neovascularization during wound healing. The inducible endoplasmic reticu-
lum chaperone oxygen-regulated protein 150 (ORP150) is expressed in human wounds along with
VEGF. Colocalization of these two molecules was observed in macrophages in the neovasculature,
suggesting a role of ORP150 in the promotion of angiogenesis. Local administration of ORP150
sense adenovirus to wounds of diabetic mice, a treatment that efficiently targeted this gene prod-
uct to the macrophages of wound beds, increased VEGF antigen in wounds and accelerated repair
and neovascularization. In cultured human macrophages, inhibition of ORP150 expression caused
retention of VEGF antigen within the endoplasmic reticulum (ER), while overexpression of ORP150
promoted the secretion of VEGF into hypoxic culture supernatants. Taken together, these data sug-
gest an important role for ORP150 in the setting of impaired wound repair and identify a key,
inducible chaperone-like molecule in the ER. This novel facet of the angiogenic response may be
amenable to therapeutic manipulation.
J. Clin. Invest. 108:41–50 (2001). DOI:10.1172/JCI200111772.
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therapeutic target for modulation of angiogenesis,
expression of the inducible ER chaperone ORP150.
Methods
Materials. For Western blot analysis, anti-human
ORP150 Ab (1 µg/ml) (14), GRP78 (0.2 µg/ml; Stress-
Gen Biotechnologies Corp., Victoria, British Colum-
bia, Canada), trans-Golgi network-38 (TGN38) (1
µg/ml; Transduction Laboratories, Lexington, Ken-
tucky, USA), RAGE (0.2 µg/ml) (18), HSC70 (0.2
µg/ml; StressGen Biotechnologies Corp.), anti-KDEL
mAb (0.2 µg/ml; StressGen Biotechnologies Corp.),
which recognizes GRP78 and GRP94, and anti-VEGF
Ab (0.2 µg/ml; Santa Cruz Biotechnology Inc., Santa
Cruz, California, USA) were used. We used anti-human
ORP150 IgG (5 µg/ml), anti-VEGF IgG (1 µg/ml;
Santa Cruz Biotechnology Inc.), anti-CD68 IgG (5
µg/ml, DAKO Japan, Tokyo, Japan), or anti–platelet-
endothelial cell adhesion molecule-1/CD31 (PECAM-
1/CD31) IgG (1 µg/ml; Santa Cruz Biotechnology
Inc.) for immunohistochemical analysis.
Cell culture and induction of hypoxia. Macrophages were
prepared from human peripheral blood cells as
described (19). In brief, monocytes were separated from
human peripheral blood by density-gradient centrifu-
gation (Histopaque 1077; Sigma Chemical Co. St.
Louis, Missouri, USA) and cultured and differentiated
for 7–10 days in RPMI-1640 containing 10% human
serum. The cultures were then exposed to hypoxia as
described previously (20). Where indicated, cells were
cultured either in the presence or in the absence of
sodium nitroprusside (SNP), as described (21).
Immunohistochemical analysis of wounds and macrophages.
Human wound samples were obtained from patholog-
ic specimens under the auspices of an approved insti-
tutional review board protocol. Immunohistochemical
analysis was performed as described previously (13).
Western blot analysis and immunoprecipitation. Western
blot analysis was performed as described previously (22).
Interaction of ORP150 and VEGF was assessed by
immunoprecipitation using anti-ORP150 IgG (3 µg/ml)
and anti-VEGF IgG (0.5 µg/ml) as described (13).
Construction of adenovirus vectors. Replication-defi-
cient recombinant adenovirus vector containing the
cDNA for ORP150 was constructed according to the
COS/TPC method as described (23). Briefly, the full-
length cDNA for rat ORP150 was subcloned in the
sense or antisense orientation into the expression unit
of pAxCAwt. The desired recombinant adenoviruses,
generated by homologous recombination, were desig-
nated Ad/S-ORP150 (sense) and Ad/AS-ORP150
(antisense) and were grown in 293 cells and purified
by cesium chloride gradient centrifugation followed
by extensive dialysis.
RT-PCR. RT-PCR was performed as described (12).
The following primers were derived from the human
VEGF sequence: 5′-TTC TAC AAT GAG CTG CGT GTG GC-
3′, 5′-CTC ATA GCT CTT CTC CAG GGA GGA-3′. The
amount of VEGF transcript was semiquantitatively
assessed by comparison with the PCR product of either
the β-actin or GAPDH transcript amplified simultane-
ously as an internal control (12, 24).
The fractionation of cultured human macrophages. The
fractionation of cultured human macrophages was
performed as described (25). In brief, human
macrophages (about 107 cells) were homogenized by
nitrogen cavitation and centrifuged at 5,000 g for 30
minutes at 4°C. The supernatant was then subjected
to ultracentrifugation (100,000 g) at 4°C for 3 hours
in buffer containing HEPES (20 mM, pH 7.4), KCl
(100 mM), NaCl (20 mM), EDTA (5 mM), PMSF (1
mM), and a sucrose step gradient (38, 30, and 20%).
The pellet (fraction 1) was resuspended, the layered
fractions (fractions 2–5) were collected, and each frac-
tion was subjected to Western blot analysis using Ab’s
against markers specific for various cellular organelles,
i.e., ER (GRP78), Golgi apparatus (TGN38), plasma
membrane (RAGE), and cytosol (HSC70).
Determination of VEGF, bFGF, and TGF-β1. Elabora-
tion of VEGF, bFGF, and TGF-β1 antigen was
assessed using a commercially available kit (R&D Sys-
tems Inc., Minneapolis, Minnesota, USA) according
to the manufacturer’s instructions. To assess VEGF
antigen in the cell supernatant, cultured human
macrophages (2 × 105 cells) were cultured in serum-
free medium. To assess VEGF antigen in the ER frac-
tions, fractions were also diluted in PBS (0.2 ml) con-
taining Nonidet P-40 (0.5%), followed by the
determination of VEGF antigen by ELISA as described
above. The protein content was measured using the
method described by Lowry (26).
Secondary intention wound-healing model. Full-thickness
excisional skin wounds using 6-mm skin biopsy
punches were made on the backs of 8-week-old
C57BL/6J (wild-type mice) or 8-week-old C57BL/6J-
m+/+ Leprdb homozygous mice (db/db mice) (both
obtained from the Jackson Laboratory, Bar Harbor,
Maine, USA), as described (27). For the evaluation of
efficiency of adenovirus infection in wounds, the indi-
cated amount of Ad/S-ORP150, Ad/AS-ORP150,
AxCALacZ (28), or AxGFP (green fluorescent protein),
provided by Riken (The Institute of Physical and
Chemical Research, Tokyo, Japan) was diluted in PBS
(0.2 ml) and administered subcutaneously at each
square 2 mm from the wound edge 2 days after the
injury, using a Hamilton gas-tight syringe with a 28G
needle. Wound tissue was dissected using 10-mm skin
biopsy punches 5 days after the injury. The number of
cells positive for F4/80 in granulation tissue and the
ratio of GFP-positive cells to F4/80-positive cells were
counted by two investigators blinded to the experi-
mental protocol. The tissue content of ORP150 was
determined by ELISA analysis as described (29).
To assess the role of ORP150 in wound healing, skin
wounds of the indicated size (6 or 12 mm) were made
on the backs of 8-week-old wild-type or 8-week-old
db/db mice as described above. The wound was digi-
tally photographed, and the wound area was calculat-
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ed using PhotoShop software (Adobe Systems Inc.,
Tokyo, Japan). After fixation, the wound tissue was
cut in 5-µm sections, frozen, and then stained with
hematoxylin and eosin (H&E) or Masson’s trichrome.
Each slide was assigned a histologic score ranging
from 1 to 12 as described (27). Briefly, the scoring was
based on the degree of the cellular invasion, granula-
tion tissue formation, vascularity, and re-epithelial-
ization. To assess the extracellular VEGF antigen of
wound tissue, the tissues were homogenized with
PBS, centrifuged at 2000 g, and the supernatant was
then subjected to ELISA as described above. For the
evaluation of neovascularization during wound heal-
ing, the density of vascular structures was determined
by immunostaining with anti–PECAM-1/CD31 IgG
(1 µg/ml) (30), followed by quantitative analysis.
Briefly, each slide was digitally photographed and
captured using PhotoShop software. Using a freehand
drawing tool, the wound bed was outlined, and the
area of the wound bed was measured. The measure-
ment of the PECAM-1–positive area within the
wound bed was also performed. To assess the vessel
density, the following formula was used: % vascular-
ization = (PECAM-1–positive area/total wound bed
area) × 100. These two assays were preformed by two
investigators blinded to the experimental protocol.
Statistical analysis was performed by using either
a nonpaired t test or ANOVA followed by multiple
comparison analysis. Where indicated, data were
analyzed by two-way ANOVA followed by multiple
contrast analysis.
Results
Expression of ORP150 in human wounds. Immunohisto-
chemical analysis of a human wound granular tissue
was performed at 10 days after injury, as indicated by
the open box in Figure 1a. Examination of the edge at
higher magnification showed the accumulation of cells
positive for ORP150, where the accumulation of CD68
signals, a marker for human macrophages (16), and
VEGF signals was demonstrated in adjacent sections
(Figure 1, b–d, indicated by the filled arrowheads). Scat-
tered CD31 signal in the same area suggested the occur-
rence of neovascularization (Figure 1e). Furthermore,
an immunofluorescence study demonstrated that
ORP150 signals in the granulation tissue (Figure 1, f
and i) overlapped, at least in part, with CD68 signals
(Figure 1, g and h) and VEGF signals (Figure 1, j and k).
We have extended the immunohistochemical analysis
with ten samples, which showed a similar tendency.
Role of ORP150 in the elaboration of VEGF by macrophages.
In view of the known role of macrophages in neovas-
cularization of wounds (31), we hypothesized that
ORP150 might participate in cellular processing of
secreted proteins, such as VEGF, released by
macrophages under hypoxic conditions. Exposure of
cultured macrophages to hypoxia (pO2 ≈ 10 torr in the
medium) resulted in time-dependent release of VEGF
antigen into culture supernatants (Figure 2a), as well
as an increase in VEGF transcripts (Figure 2b). Consis-
tent with our previous observations (16), expression of
ORP150 was also strongly enhanced in hypoxic
macrophages (Figure 2c). These results led us to per-
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Figure 1
ORP150 expression in healing human wound. (a–e) A
human wound (31-year-old male) was analyzed either
by H&E staining (×2) (the area indicated by open box
was further studied in b–k) or immunohistochemical-
ly using anti-ORP150 (×40) (b), anti-CD68 Ab (×40)
(c), anti-VEGF Ab (×40) (d), or anti-CD31 Ab (×40)
(e), followed by visualization with the peroxidase
method. (f–h) Sections adjacent to b (areas indicated
by filled arrowheads) were double-stained with anti-
ORP150 Ab (f) and anti-CD68 Ab (g). Both images
were digitally overlapped (×100) (h). (i–k) Sections
adjacent to f were double-stained with anti-ORP150
Ab (i) and anti-VEGF Ab (j). Both images were digital-
ly overlapped (×100) (k). Open arrowheads in a
denote the edge of the granulation tissue. See text for
the description of filled arrowheads in b–e.
form immunoprecipitation analyses to determine if
ORP150 and VEGF might interact; lysates of hypoxic
macrophages were immunoprecipitated with anti-
ORP150 IgG, and the immunoprecipitates were sub-
jected to SDS-PAGE and immunoblotting with anti-
VEGF IgG. A prominent immunoreactive band was
observed (VEGF; Figure 2d, left panel). Alternatively,
when a complementary protocol was followed in which
immunoprecipitation was performed with anti-VEGF
IgG and immunoblotting employed anti-ORP150 IgG,
an antigen of ORP150 was detected in precipitants
(ORP150; Figure 2d, right panel). Studies in which
either purified ORP150 or recombinant VEGF were
immunoprecipitated with Ab to either VEGF or
ORP150 demonstrated that anti-ORP150 does not
react with VEGF and that anti-VEGF does not cross-
react with ORP150 (not shown). Immunocytochem-
istry also showed ORP150 and VEGF to be present in
an overlapping distribution within the cell (Figure 2,
e–g), although VEGF immunoreactivity was also
detected in the pericytoplasmic space (Figure 2, f and
g), while ORP150 is present in the ER (Figure 2e) (13).
These data suggested that ORP150 binds to VEGF in
the ER and may participate in protein transport as part
of the secretory pathway.
To further assess the possibility of a role for ORP150
in the secretory pathway of VEGF, levels of ORP150
were modulated in macrophages using adenoviruses
coding for ORP150 in the sense (Ad/S-ORP150) or
antisense (Ad/AS-ORP150) orientation. The efficiency
of viral infection into the cultured macrophages
assessed using AxGFP (100 moi) was approximately
equal to 80% in macrophages, although the efficiency
was quite low in freshly prepared monocytes, as
described previously (32, 33).
Treatment of human macrophages with Ad/AS-
ORP150 suppressed hypoxia-mediated induction of
ORP150 in macrophages, whereas treatment with Ad/S-
ORP150 resulted in the increase of ORP150 (Figure 3a,
upper panel). In contrast, treatment with an adenovirus
overexpressing either LacZ (AxCALacZ) or GFP (AxGFP,
100 moi in each case) had no effect on ORP150 levels in
hypoxic cultures (Figure 3a, upper panel). In each case,
the levels of GRP78 and GRP94, other molecular chap-
erones in the ER, remain unchanged (Figure 3a, lower
panels). Infection of hypoxic macrophages with aden-
oviruses encoding LacZ or ORP150 in the sense/anti-
sense orientation (100 moi) had no effect on the level of
VEGF, β-actin, or GAPDH transcripts (Figure 3b).
ELISA analysis of VEGF in subcellular fractions (con-
firmed by Western blot analysis using markers specific
to each organelle; Figure 3c) revealed an increase in
VEGF content of the ER fraction in cultured
macrophages subjected to hypoxia after infection with
Ad/AS-ORP150, compared with that in cells infected
with AxCALacZ (Figure 3d). Consistently, ELISA of
VEGF antigen in the supernatant of hypoxic
macrophages infected with various amounts of Ad/AS-
ORP150 showed a dose-dependent decrease in the cul-
ture supernatant (approximately threefold; Figure 3g).
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Figure 2
Expression of VEGF and ORP150 in human macrophages exposed to
hypoxia. (a) Macrophages were either exposed to hypoxia (filled bars;
0–24 hours) or maintained under normoxic conditions (open bars).
VEGF content in the culture supernatant was measured by ELISA as
described in the text (n = 8; mean ± SD). *P < 0.01 by multiple con-
trast analysis. (b–d) Macrophages were exposed to hypoxia (0–24
hours). (b) RNA was prepared at the indicated times and subjected
to RT-PCR analysis using primers for either VEGF (upper panel) or 
β-actin (lower panel). Protein extracts were prepared and subjected
to Western blot analysis using anti-human ORP150 Ab (c). Cell lysates were incubated with either anti-human ORP150 Ab or anti-VEGF Ab.
(d) The immunoprecipitant was separated in SDS-PAGE (8–12%; nonreducing condition for VEGF and reducing condition for ORP150) and
subjected to Western blot analysis using either anti-VEGF Ab (left panel) or anti-ORP150 Ab (right panel). Migrations of molecular-weight
markers are shown in the middle. The filled circles denote the signals derived from IgG used as primary Ab. (e–g) Human macrophages were
double-stained with anti-ORP150 Ab (e) and anti-VEGF Ab (f). VEGF and ORP150 signals were digitally overlapped (×400) (g).
The VEGF content in the ER showed no significant
decrease by the infection of cultured macrophages with
Ad/S-ORP150 (Figure 3e), however, infection of cul-
tured macrophages with Ad/S-ORP150 increased the
level of VEGF antigen in the culture supernatant (Fig-
ure 3h). To further clarify the role of ORP150 in the
secretory pathway of VEGF in response to stimuli other
than hypoxia, SNP, an NO liberator (21), was added to
macrophages infected with AxCALacZ, Ad/S-ORP150,
and Ad/AS-ORP150 (100 moi) (23). Under normoxic
conditions, addition of SNP (10 µM) elevated the levels
of VEGF antigen in the supernatant (approximately
equal to an eightfold increase), with no significant dif-
ferences among cells infected with AxCALacZ, Ad/S-
ORP150, or Ad/AS-ORP150 (data not shown). In con-
trast, treatment with Ad/AS-ORP150 caused a marked
retention of VEGF in ER under hypoxic conditions,
especially in cultures stimulated by SNP (Figure 3f),
with the decrease of VEGF elaboration (Figure 3i).
Treatment with Ad/S-ORP150 resulted in the decrease
of VEGF antigen in ER, with the marked increase in
VEGF production (Figure 3, f and i), suggesting a role
of ORP150 in the optimized secretion of VEGF under
hypoxia. Under these conditions, treatment of hypoxic
cultures with Ad/AS-ORP150 did not alter cell viability
up to the longest time examined, 48 hours (not shown).
Immunocytochemical analysis demonstrated that the
localization of VEGF immunoreactivity was also
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Figure 3
Dependence of VEGF processing on ORP150 in hypoxic
macrophages. (a and b) Macrophages were exposed to hypoxia
in the presence of Ad/S-ORP150, Ad/AS-ORP150, AxCALacZ,
or AxGFP. Cell lysates were subjected to Western blot analysis
using either anti-ORP150 Ab (a) (upper panel) or anti-KDEL
mAb’s (lower panels). RNA was also prepared from cells incu-
bated in the presence of adenovirus. (b) RT-PCR analysis was
performed using primers specific for either VEGF (upper panel),
β-actin (middle panel), or GAPDH (lower panel). (c) Cell lysates
were fractionated, as described, and fractions corresponding to
ER (lanes 1 and 2), Golgi apparatus (lane 3), plasma membrane
(lane 4), and cytosol (lane 5) were subjected to immunoblot
analysis using cellular organelle-specific Ab’s. (d–i) Cultured
macrophages were infected with AxCALacZ (100 moi), Ad/S-
ORP150 (0–100 moi), or Ad/AS-ORP150 (0–100 moi), and fur-
ther incubated under hypoxic conditions for 24 hours, either in
the absence (d, e, g, and h) or presence (f and i) of SNP. The
content of VEGF antigen in the ER fraction (d–f) and culture
supernatant (panels g–i) was measured by ELISA as described (n = 6; mean ± SD). *P < 0.01 compared with AxCALacZ-treated culture by
either multiple comparison analysis (d, g, h, and f) or multiple contrast analysis, following two-way ANOVA (i). (j–o) Macrophages were
infected with either AxCALacZ (j–l) or Ad/AS-ORP150 (m–o) and immunostained with either anti-KDEL mAb (j and m) or anti-VEGF mAb.
(l and o) Both images were digitally overlapped. ×400.
observed in the pericytoplasmic space in macrophages
infected with AxCALacZ (Figure 3, j–l), whereas the
localization of VEGF immunoreactivity was observed
only in the perinuclear space, which overlapped the sig-
nals obtained from anti-KDEL Ab, in hypoxic
macrophages infected with Ad/AS-ORP150 (Figure 3,
m–o). These data indicate that ORP150 mediates the
intracellular transport of VEGF in human
macrophages, especially under hypoxic conditions.
Role of ORP150 in wound healing. To assess the effi-
ciency of adenovirus in mouse wounds, a series of his-
tochemical analyses were performed in db/db mice
after infection with recombinant adenovirus vector
(Figure 4a; H&E staining is shown for orientation).
First, fluorescent microscopic analysis revealed an
overlap of cells positive for F4/80 (specific for murine
macrophages) and GFP-positive cells in granulation
tissue of mouse wounds (Figure 4, b–d). The latter
increased in parallel with the titer of coinfected aden-
ovirus (Ad/SORP150 and AxGFP), whereas coinfection
with Ad/S-ORP150 and AxCALacZ did not induce flu-
orescent cells (Figure 4i). The number of GFP-positive
cells reached a maximum 2–3 days after the viral infec-
tion, and signals could be detected up to 10 days after
the viral infection (data not shown). Second, statisti-
cal analysis using F4/80 as a marker revealed the
increase of overlap of GFP-positive cells with
macrophages in a dose-dependent manner, showing
maximal overlap (about 50%) at 108 pfu (Figure 4j),
though there were far less positive GFP signals derived
from keratinocytes (data not shown). Third, coinfec-
tion of AxGFP and Ad/S-ORP150 showed the colocal-
ization of signals derived from GFP fluorescence and
ORP150 antigen (Figure 4, e–g), which, at least in part,
overlapped with signals of F4/80 (Figure 4h). The
increase in ORP150 antigen induced by adenovirus
infection occurred in a dose-dependent manner (Fig-
ure 4k). By contrast, coinfection of AxCALacZ and
AxGFP failed to increase ORP150 antigen level in tis-
sue. These data suggest that adenovirus infection
occurred mainly in macrophages during wound heal-
ing, and the efficiency of infection was maximal (about
50% using GFP as a marker) with 0.5 × 108 to 1 × 108
pfu. Consequently, further experiments were carried
out with 5 × 107 pfu and 2 × 108 pfu for 6-mm and 12-
mm wounds, respectively.
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Figure 4
Characterization of wounds infected with adenovirus. (a–h) Two days after the introduction of a wound (6 mm in diameter) in db/db
mice, a mixture of adenovirus (AxGFP and Ad/S-ORP150; 5 × 107 pfu each) was administered at each wound, as described. Two days
after the infection, the tissue was sampled and subjected to H&E staining (×4) (a), immunostaining with anti-F4/80 Ab (×40) (b), or
visualization of GFP signal by fluorescent microscopy (×40) (c). Signals derived from F4/80 and GFP were digitally overlapped (×40)
(d). (a) Filled arrowheads indicate the initial wound area, and the open arrowheads indicate the edge of the granulation tissue. (e–h)
Granulation tissue was stained with anti-ORP150 Ab and signals derived from (e) GFP (×40) and (f) ORP150 (×40) were visualized by
fluorescent microscopy. (g) Signals of GFP and ORP150 were digitally overlapped. (×40.) (h) The adjacent section was immunostained
with anti-F4/80 Ab. (×40.) (i–k) Either the indicated amount of AxGFP and Ad/S-ORP150 (open bars) or (i and j) AxCALacZ and Ad/S-
ORP150 (108 pfu each; filled bars), or (k) AxCALacZ and AxGFP (108 pfu each; filled bar) was administered, as described. Three days
after the infection, either GFP-positive cells (i) or the percentage of GFP-positive cells in F4/80-positive cells (j) was counted in the gran-
ulation tissue as described in the text. The content of tissue ORP150 antigen was assessed by ELISA as described. (k). For i–k, n = 6,
mean ± SD. *P < 0.01 by multiple comparison analysis.
To examine the effect of ORP150 on wound healing,
a secondary intention wound-healing model was
employed in genetically diabetic mice (C57BL/6J-m+/+
Leprdb homozygous mice). Because this model has been
used to study the effects of growth/angiogenic factors,
we know that the reparative response is delayed and his-
tologic scoring of these wounds shows diminished
epithelialization (27, 34). Consistent with these previ-
ous observations, wound repair was delayed in
C57BL/6J-m+/+ Leprdb homozygous mice (db/db) admin-
istered AxCALacZ, with only about 40% closure by days
9–12 (Figure 5, a and b, open bars) and low histologic
scores (Figure 5c, open bars), whereas heterozygous
(db/–) mice were virtually completely healed by this time
(not shown). We hypothesized that overexpression of
ORP150 in diabetic wounds, using an adenovirus strat-
egy (Ad/S-ORP150), would accelerate wound repair.
Topical treatment of db/db animals with the same titer
of Ad/S-ORP150 as was used for AxCALacZ controls
resulted in accelerated wound closure (Figure 5, a and
b, filled bars) and an increase in histologic score (Figure
5c), approximating that which was observed in control
animals. By the same logic we reasoned that suppres-
sion of ORP150 would attenuate wound repair in
C57BL/6J (wild-type) mice. Local administration of
Ad/AS-ORP150 delayed the wound repair (Figure 5, d
and e, filled bars) and caused a decrease in histologic
score (Figure 5f). The administration of an inert virus
had an effect on wound repair similar to that observed
with AxCALacZ (data not shown).
Contribution of ORP150 to neovessel formation in wounds.
To study the role of ORP150 expression on wound
healing in further detail, we performed immunoblot
analysis on murine wound tissue after infection of
wounds with the different adenoviruses, this time
using wounds of a smaller size (diameter 6 mm) to
facilitate quantitative analysis of vascularization and
VEGF content. In diabetic mice, local administration
of Ad/S-ORP150 accelerated the wound healing (Fig-
ure 6a), along with approximately fourfold increased
levels of ORP150 antigen (Figure 6b) compared with
wound tissue infected with AxCALacZ, as assessed by
the densitometric analysis (Figure 6c). Immunohisto-
chemical analysis demonstrated the increased expres-
sion of ORP150 led to angiogenic foci by day 6 after
wounding (not shown). In parallel, increased ORP150
expression in diabetic wounds caused the increase of
neovessel-occupied area in granulation tissue of db/db
mice treated with Ad/S-ORP150, compared with those
receiving the AxCALacZ virus (Figure 6d), as well as the
marked increase in tissue levels of extracellular VEGF
by day 6 (Figure 6e).
To further confirm the role of ORP150 in wound heal-
ing, counterpart experiments were performed in wild-
type mice. In wild-type mice, administration of Ad/AS-
ORP150 delayed wound healing (Figure 6f), and wound
tissue treated with Ad/AS-ORP150 displayed reduced
ORP150 antigen up to day 6, compared with wound tis-
sue treated with AxCALacZ virus (Figure 6, g and h).
Local administration of Ad/AS-ORP150 in wounds of
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Figure 5
Effect of ORP150 on wound closure. A second-
ary intention wound (12 mm in diameter) was
introduced in either C57BL/6J-m+/+ Leprdb (db/db)
mice or C57BL/6J (wild-type) mice. Photographs
of the wounds are shown on days 3 and 9 after
induction of the wounds (a and d). The db/db
mice were treated with either AxCALacZ (LacZ)
or Ad/S-ORP150 (sense), and wild-type mice
were treated with either Ad/AS-ORP150 (anti-
sense) or AxCALacZ. In each case, 2 × 108 pfu of
adenovirus was subcutaneously injected at each
octal angle of the wound 2 mm from the edge.
Wound closure, shown as percentage of area of
the initial wound (b and e) and histologic score
(c and f) were determined on the indicated day
after wounding: db/db mice were treated with
AxCALacZ (db/db + LacZ) or Ad/S-ORP150
(db/db + sense), and wild-type were treated with
AxCALacZ (wild-type + LacZ) or Ad/AS-ORP150
(wild-type + antisense). n = 4,; mean ± SD. *P <
0.01 by multiple contrast analysis.
wild-type mice showed delayed granulation (not shown)
and angiogenesis (Figure 6i), along with suppression of
extracellular VEGF antigen by day 6 (Figure 6j).
To examine the effect of other factors on wound heal-
ing, tissue contents of bFGF and TGF-β1 were assessed
in the same way as for VEGF in both db/db mice and
wild-type mice, and no significant changes of these fac-
tors were detected in db/db mice treated with either
Ad/S-ORP150 or AxCALacZ or in wild-type mice treat-
ed with either Ad/AS-ORP150 or AxCALacZ (data not
shown). In both experiments, number of CD68-positive
cells showed no significant difference between wound
tissue infected with Ad/S-ORP150, Ad/AS-ORP150, or
AxCALacZ (data not shown).
Discussion
One of the salient features of the cellular biosynthetic
response to hypoxia is redirection of protein synthesis
with production of ORPs, which overlap with glucose-
regulated proteins (GRPs) (11, 14, 35, 36). Common
denominators of this group of polypeptides include
their placement in the heat-shock protein family, the
presence of ER retention sequences, and their proper-
ties as molecular chaperones in the ER-to-Golgi trans-
fer of newly synthesized proteins (37). Since
ORPs/GRPs are induced by hypoxic stress in a wide
range of tissues, their expression indicates that cellular
components in wounds execute a stress response to the
insufficient blood supply. Colocalization of ORP150
with VEGF found at macrophages in human wounds
(Figure 1) suggests that these two molecules contribute
in a complementary manner to the evolving stress
response, at least in an early step in a series of reactions
to achieve wound healing.
Since VEGF requires posttranslational processing
(38–40), we considered the possibility that in the set-
ting of cellular stress imposed by hypoxia, optimal
function of molecular chaperones would be essential
for secretion of mature VEGF. Our current observa-
tions demonstrate binding of ORP150 to VEGF in
hypoxic macrophages. Suppression of ORP150 in
hypoxic macrophages inhibited elaboration of VEGF,
resulting in retention of this peptide in the ER. This is
consistent with our previous observation that ORP150
binds to the ER form of the 80-kDa glycoprotein
(GP80), a major secretory protein in Madin-Darley
canine kidney cells, and provides a more efficient path-
way for protein transport due to its higher affinity for
ATP than that of GRP78 (41). In addition, we have
found that ORP150 enhanced elaboration of neu-
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Figure 6
ORP150 content in wounds after infection with
recombinant adenoviruses. A secondary intention
wound model (6 mm in diameter) was introduced
in C57BL/6J-m+/+ Leprdb homozygous mice (db/db)
(a–e) and C57BL/6J mice (wild-type) (f–j). Two
days after the injury, recombinant adenovirus (5 ×
107 pfu each) was administered as described above.
Photographs of the wounds are shown on days 3
and 9 after induction of the wounds (a and f). At
the indicated time points, wounds were sampled
(10 mm diameter), and protein extracts were pre-
pared from the wound tissue and subjected to
Western blot analysis with anti-ORP150 Ab. A typ-
ical example of four repeated experiments is shown
(b and g). Densitometric analysis of multiple West-
ern blots was performed in (c) (db/db mice) and (h)
(wild-type mice). *P < 0.01 by multiple contrast
analysis. (d and i) Angiogenesis was estimated
semiquantitatively 7 days after the injury based on
the area occupied by PECAM-1 immunoreactive tis-
sue. n = 6; mean ± SD. **P < 0.01 by nonpaired t
test. (e and j) Tissue VEGF content was measured
in wound tissue. n = 6; mean ± SD. *P < 0.01 by
multiple contrast analysis. Statistics were per-
formed in comparison with animals infected with
AxCALacZ (open bars) in each panel.
rotrophic peptide in cultured neurons exposed to
hypoxia and in an ischemic brain (42). These data sug-
gest that ORP150 functions as molecular chaperone
under hypoxia to facilitate the protein transport/pro-
cessing in ER, though not specific to VEGF.
In the wound-healing process, macrophages infil-
trating the wound site produce and secrete various
kinds of cytokines or growth factors (2). TGF-β1 and
bFGF are known to be important factors secreted by
macrophages in healing wounds; however, their levels
showed no significant change in the wound tissues
infected with adenovirus overexpressing ORP150 sense
or antisense orientation mRNA. In contrast, while not
affected by the levels of ORP150 in normoxia, SNP-
induced VEGF production was much enhanced by the
overexpression of ORP150 under hypoxic condition.
Since nitric oxide (NO) liberator is known to suppress
hypoxia-mediated induction of VEGF at the transcrip-
tion level (43), it is possible that the beneficial effect of
ORP150 functions mainly on posttranslational pro-
cessing/export in the ER under hypoxia.
In diabetic wounds, in which one key facet of
impaired repair is diminished evidence of vascular in-
growth (Figure 6d), we found decreased levels of
ORP150 (Figure 6, b and c), because impaired stress
response has been observed in the diabetic condition
(44). Though the efficiency of infection was lower than
the previous report (45), overexpression of ORP150 in
wounds of diabetic mice had a beneficial effect. This is
probably because even with only a limited number of
cells displaying increased levels of ORP150 as a conse-
quence of the viral infection procedure, their produc-
tion of paracrine factors, such as VEGF, changed the
course of wound repair by impacting on many cells in
the local environment. As shown in Figure 3i, in cul-
tured cells, the suppression of ORP150 is crucial for
VEGF elaboration (by about 20 times suppression),
especially when other factors exist that promote the
VEGF production at the transcriptional level (e.g., NO
or other cytokines). In contrast, manipulation of the
ORP150 level in vivo resulted in modification of tissue
VEGF content to only a small extent (twofold to three-
fold increase in diabetic wounds, for instance). The
infection efficiency of adenovirus and the numbers of
copies of cDNA introduced in tissue (Figure 4) would
be less than those observed in in vivo experiments (Fig-
ure 3), which resulted in the small modification of
VEGF secretion in wounds even with the existence of
many factors functioning to boost the elaboration of
VEGF. However, the data demonstrated here would at
least claim that the optimization of protein transport
by the expression of molecular chaperons could be a
novel therapeutic target.
Taken together, these data highlight the role of ER
chaperones in the cellular response to stress and sug-
gest a new level of intervention, bolstering expression
of ORP150 in settings such as impaired wound repair
where protein processing events in the ER may limit the
pace and completeness of repair.
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